Sermorelin

Sermorelin is one of the oldest peptides in the “growth hormone” group, and unlike most of its cousins it actually held FDA approval at one point. People often lean on that history to suggest it does more than the evidence really backs up.

What it is

Sermorelin is a lab-made peptide (a short chain of amino acids, the building blocks of proteins) built from 29 amino acids — specifically the first 29 of a natural hormone called growth hormone-releasing hormone, or GHRH. That opening stretch is the part that does the work. Sermorelin latches onto the GHRH receptor (a docking site for the hormone) on the pituitary, a small gland at the base of the brain, and signals it to release its own growth hormone (GH).

Because it acts one step upstream — telling the gland to do its normal job — your body’s built-in “off switch,” a hormone called somatostatin, still works. So the growth hormone comes out in natural bursts rather than as one steady flood. Sermorelin is given as a shot under the skin (subcutaneous), and the body clears it fast, with a half-life (the time it takes for half of a dose to break down) of about 11 to 12 minutes.

The claims

Clinics pitch sermorelin for anti-aging, more lean muscle and less fat, better sleep, quicker recovery, and more energy. It’s usually sold as a “natural” or “safer” stand-in for injected human growth hormone, since the idea is that it coaxes your body into making its own rather than pumping it in from outside.

What the evidence actually shows

The best human data is decades old and pretty narrow. In children with idiopathic growth hormone deficiency (low GH with no clear cause), daily sermorelin sped up growth in some kids over 12 months — though the gains were generally smaller than with standard somatropin (a synthetic version of growth hormone). It was also used as a diagnostic test to check how much GH the pituitary could produce (BioDrugs review, 1999).

In adults, the study people cite most is small and early. It was a single-blind, placebo-controlled trial (meaning participants didn’t know if they got the real drug or a dummy, and some received a placebo for comparison) of nineteen older men and women, aged 55-71, run over about five months. A GHRH(1-29) analogue raised GH and IGF-1 (a blood marker that tends to rise when growth hormone goes up) and produced a modest gain in lean mass — but only in the men, not the women (Khorram et al., JCEM, 1997).

That’s a genuine sign that the mechanism works. But it’s a tiny, short study. There are no large, modern randomized controlled trials (the gold-standard test where people are randomly assigned to a treatment or a comparison group) showing the marketed perks — fat loss, better sleep, faster recovery, “younger” aging — in healthy adults. And nudging a blood marker like IGF-1 upward isn’t the same as proving a real-world health benefit.

Legal and regulatory status

Sermorelin was FDA-approved under the Geref name — first in 1990 (Geref Diagnostic) as a tool for checking GH secretion, then in 1997 (Geref) for growth hormone deficiency in children. The maker pulled it from the market around 2008 for commercial reasons, and the approvals were later withdrawn. The FDA went on to confirm that it wasn’t taken off the market for safety or effectiveness problems (Federal Register, 2013).

As of 2026, there’s no FDA-approved sermorelin product for sale. Anything prescribed today is mixed up by compounding pharmacies (pharmacies that prepare custom medications), which is not the same thing as an FDA-approved finished drug. In sports, sermorelin is banned by WADA (the World Anti-Doping Agency) at all times as a growth hormone-releasing factor under category S2.

Safety

In the older trials and in pediatric use, short-term tolerability was good. The most common side effects were brief facial flushing and some pain or redness at the injection site. Because it works through your body’s own self-regulating GH pathway, a runaway overshoot is less likely than with injected GH.

That said, the long-term safety of using it for anti-aging in healthy adults simply hasn’t been studied. And the theoretical worries that come with raising GH and IGF-1 — possible effects on blood sugar, fluid retention, and unknown implications for cancer risk — haven’t been ruled out. On top of that, compounded products can vary in how pure they are and how much active ingredient they contain. None of this is medical advice.

Bottom line

Sermorelin does reliably prompt the pituitary to release growth hormone, and it has real (if dated) human data in growth hormone deficiency. But the popular adult anti-aging and body-composition claims rest on small, old, short studies and indirect markers — not solid modern results. The mechanism is real; the marketing is running well ahead of the evidence.

Evidence grade: 8/10 · Good.

Sources

• Sermorelin — Wikipedia
• Determination That GEREF (Sermorelin Acetate) Injection Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness — Federal Register (2013)
• Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997;82(5):1472-1479.
• Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. (PubMed)
• WADA Prohibited List (S2. Peptide Hormones, Growth Factors, Related Substances and Mimetics)